RT Journal Article
T1 Effectiveness of aprepitant in post-acute COVID19 syndrome
A1 Reinoso-Arija, Rocío
A1 López-Ramírez, Cecilia
A1 Jimenez-Ruiz, José Antonio
A1 López-Campos, José Luis
K1 Aprepitant
K1 Post-acute
K1 COVID19
K1 SARS-CoV-2
K1 Atención subaguda
K1 Infecciones por coronavirus
K1 Síndrome
K1 Salud
AB This is the first case of a patient taking aprepitant for a post-acute COVID-19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.
PB John Wiley & Sons Ltd
YR 2021
FD 2021-09-18
LK http://hdl.handle.net/10668/3958
UL http://hdl.handle.net/10668/3958
LA en
NO Reinoso-Arija R, López-Ramírez C, Jimenez-Ruiz JA, López-Campos JL. Effectiveness of aprepitant in post-acute COVID19 syndrome. Clin Case Rep. 2021 Sep 18;9(9):e04646
DS RISalud
RD Apr 8, 2025